Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NOTCH2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NOTCH2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NOTCH2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NOTCH2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NOTCH2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NOTCH2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000189025 | Thyroid | HT | placenta development | 19/1272 | 144/18723 | 4.08e-03 | 2.99e-02 | 19 |
GO:00022745 | Thyroid | HT | myeloid leukocyte activation | 26/1272 | 223/18723 | 4.98e-03 | 3.36e-02 | 26 |
GO:000165516 | Thyroid | HT | urogenital system development | 36/1272 | 338/18723 | 4.99e-03 | 3.36e-02 | 36 |
GO:00902874 | Thyroid | HT | regulation of cellular response to growth factor stimulus | 33/1272 | 304/18723 | 5.25e-03 | 3.50e-02 | 33 |
GO:00027635 | Thyroid | HT | positive regulation of myeloid leukocyte differentiation | 10/1272 | 58/18723 | 5.30e-03 | 3.51e-02 | 10 |
GO:000257320 | Thyroid | HT | myeloid leukocyte differentiation | 24/1272 | 208/18723 | 7.69e-03 | 4.54e-02 | 24 |
GO:000726518 | Thyroid | HT | Ras protein signal transduction | 35/1272 | 337/18723 | 8.17e-03 | 4.76e-02 | 35 |
GO:00108379 | Thyroid | HT | regulation of keratinocyte proliferation | 7/1272 | 35/18723 | 8.23e-03 | 4.78e-02 | 7 |
GO:00720806 | Thyroid | HT | nephron tubule development | 13/1272 | 91/18723 | 8.36e-03 | 4.79e-02 | 13 |
GO:0032956113 | Thyroid | PTC | regulation of actin cytoskeleton organization | 182/5968 | 358/18723 | 4.64e-14 | 2.79e-12 | 182 |
GO:0032970113 | Thyroid | PTC | regulation of actin filament-based process | 197/5968 | 397/18723 | 8.91e-14 | 4.89e-12 | 197 |
GO:0001701111 | Thyroid | PTC | in utero embryonic development | 175/5968 | 367/18723 | 1.40e-10 | 4.73e-09 | 175 |
GO:000726519 | Thyroid | PTC | Ras protein signal transduction | 162/5968 | 337/18723 | 3.16e-10 | 1.02e-08 | 162 |
GO:0042060112 | Thyroid | PTC | wound healing | 190/5968 | 422/18723 | 7.72e-09 | 1.92e-07 | 190 |
GO:0048732113 | Thyroid | PTC | gland development | 193/5968 | 436/18723 | 2.88e-08 | 6.42e-07 | 193 |
GO:0001889112 | Thyroid | PTC | liver development | 79/5968 | 147/18723 | 3.08e-08 | 6.82e-07 | 79 |
GO:0061008112 | Thyroid | PTC | hepaticobiliary system development | 80/5968 | 150/18723 | 3.94e-08 | 8.55e-07 | 80 |
GO:003153220 | Thyroid | PTC | actin cytoskeleton reorganization | 60/5968 | 107/18723 | 1.91e-07 | 3.51e-06 | 60 |
GO:006156419 | Thyroid | PTC | axon development | 199/5968 | 467/18723 | 5.27e-07 | 8.53e-06 | 199 |
GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049191 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049194 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa049195 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa049198 | Colorectum | FAP | Thyroid hormone signaling pathway | 41/1404 | 121/8465 | 2.28e-06 | 4.28e-05 | 2.60e-05 | 41 |
hsa049199 | Colorectum | FAP | Thyroid hormone signaling pathway | 41/1404 | 121/8465 | 2.28e-06 | 4.28e-05 | 2.60e-05 | 41 |
hsa0491910 | Colorectum | CRC | Thyroid hormone signaling pathway | 35/1091 | 121/8465 | 2.05e-06 | 6.85e-05 | 4.64e-05 | 35 |
hsa05207 | Colorectum | CRC | Chemical carcinogenesis - receptor activation | 42/1091 | 212/8465 | 2.62e-03 | 1.75e-02 | 1.19e-02 | 42 |
hsa0491911 | Colorectum | CRC | Thyroid hormone signaling pathway | 35/1091 | 121/8465 | 2.05e-06 | 6.85e-05 | 4.64e-05 | 35 |
hsa052071 | Colorectum | CRC | Chemical carcinogenesis - receptor activation | 42/1091 | 212/8465 | 2.62e-03 | 1.75e-02 | 1.19e-02 | 42 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa0491928 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa015227 | Esophagus | ESCC | Endocrine resistance | 63/4205 | 98/8465 | 2.38e-03 | 6.58e-03 | 3.37e-03 | 63 |
hsa043306 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
hsa046585 | Esophagus | ESCC | Th1 and Th2 cell differentiation | 58/4205 | 92/8465 | 6.49e-03 | 1.60e-02 | 8.19e-03 | 58 |
hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa04919113 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa0152215 | Esophagus | ESCC | Endocrine resistance | 63/4205 | 98/8465 | 2.38e-03 | 6.58e-03 | 3.37e-03 | 63 |
hsa0433013 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
hsa0465812 | Esophagus | ESCC | Th1 and Th2 cell differentiation | 58/4205 | 92/8465 | 6.49e-03 | 1.60e-02 | 8.19e-03 | 58 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NOTCH2 | SNV | Missense_Mutation | | c.4888C>G | p.Arg1630Gly | p.R1630G | Q04721 | protein_coding | deleterious(0.03) | probably_damaging(0.95) | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
NOTCH2 | SNV | Missense_Mutation | novel | c.4163N>C | p.Ser1388Thr | p.S1388T | Q04721 | protein_coding | tolerated(1) | benign(0) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
NOTCH2 | SNV | Missense_Mutation | | c.6991G>T | p.Ala2331Ser | p.A2331S | Q04721 | protein_coding | tolerated(0.78) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NOTCH2 | SNV | Missense_Mutation | | c.3044N>C | p.Val1015Ala | p.V1015A | Q04721 | protein_coding | tolerated(0.27) | benign(0.015) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NOTCH2 | SNV | Missense_Mutation | | c.804N>T | p.Arg268Ser | p.R268S | Q04721 | protein_coding | tolerated(0.65) | benign(0.037) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
NOTCH2 | SNV | Missense_Mutation | novel | c.290N>G | p.Thr97Arg | p.T97R | Q04721 | protein_coding | tolerated(0.1) | probably_damaging(0.979) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
NOTCH2 | SNV | Missense_Mutation | rs376783592 | c.1698G>T | p.Leu566Phe | p.L566F | Q04721 | protein_coding | tolerated(0.7) | possibly_damaging(0.77) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NOTCH2 | SNV | Missense_Mutation | | c.4996N>T | p.Val1666Phe | p.V1666F | Q04721 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-B6-A0X0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NOTCH2 | SNV | Missense_Mutation | | c.4812N>T | p.Arg1604Ser | p.R1604S | Q04721 | protein_coding | tolerated(0.57) | benign(0.007) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
NOTCH2 | SNV | Missense_Mutation | novel | c.2864G>A | p.Ser955Asn | p.S955N | Q04721 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | inhibitor | MK0752 | | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | antibody | 252166663 | TAREXTUMAB | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | inhibitor | RO4929097 | RG-4733 | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | inhibitor | PF-03084014 | NIROGACESTAT | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | antibody | REGN421 | | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | | Tarextumab | TAREXTUMAB | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | | OMP-59R5 | TAREXTUMAB | |